Industries > Pharma > Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024
Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024
Post-marketing surveillance for medicines – discover trends, outlooks, and revenues
Where are pharmacovigilance and related needs heading? For those pharmaceutical testing studies you get new analysis, also exploring sales predictions. You unlock that medical industry. And you assess its results, trends, technologies, prospects, and opportunities.
Visiongain’s updated report forecasts those revenues to 2024 at overall world market, regional, and national level. There stay ahead in data, benefiting your influence. And hear about gains for patients, doctors, healthcare providers, and companies.
Read on, then, to explore assessments of drugs in use, also finding those services’ future commercial value.
Analyses exclusive to that study, discussing the most important needs and potentials
Demand rises for those testing, data storage, and monitoring operations. There our study benefits your plans, decisions, and authority by interpreting medical needs, regulations, and companies’ efforts. Save time and effort.
And you see what’s happening in surveillance of pharmaceuticals, assessing likely challenges, events, and gains. In particular discover prospects for phase IV clinical trials, contract research organisations (CROs), and pharmaceutical companies.
And in those analyses you get data found nowhere else. Our forecasting system goes to the core of sales potentials in those drug safety assessments, showing revenue predictions.
Our report gives 36 tables, 35 charts, and interviews with three companies. There you discover historical results, growth rates, market shares, discussions, and forecasts.
And the following sections show how our new investigation helps you stay ahead.
National markets – what outlooks for service demand and provision?
What’s the commercial potential of post-marketing studies for medicines? For those testing activities our work forecasts overall world spending to 2024.
Our report also gives you individual forecasts to 2024 for 12 national markets:
• United States (US)
• Germany, France, UK, Italy, and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India, and China (BRIC nations), and South Korea.
Stay ahead, then, for information. There you find regions and countries with highest demands, spending, and potential sales growth. Explore progress, needs and opportunities.
Also what events, challenges, and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and trends influencing that pharma field.
Market forces, events, and issues – developments influencing pharmacovigilance
Find what’s happening. Our new report explains issues, processes, and events affecting that industry and market from 2014, including these:
• Reporting systems for adverse drug reactions (ADRs) – their present and future, including data on reported and recorded events by year and region
• Drug approval moving towards post-marketing studies, inc. advances in therapies
• Safety monitoring using reporting from social media – explore possibilities in big data
• Improvements in data collection and communication leading to more-flexible drug approval processes – changing routes of marketing authorisation
• Strengths and weaknesses of procedures and practice in 2014, and how pharma regulatory affairs can progress there to 2024.
And it discusses these trends and influences, among others:
• Policies of national and international bodies, and regulators’ roles in present and future pharmacovigilance programmes
• Companies in business process outsourcing (BPO), software providers, regulatory consultants, and contract research organisation (CROs)
• Prediction of overall pharma R&D spending and its effects on that drug monitoring
• Collaboration between the FDA and EMA, and application of pharmacogenomics and biomarkers
• Use of electronic health record (EHR) systems – a live model for drug safety, applying information systems.
There you explore political, economic, social, and technological questions. See too how post-approval R&D lets companies benefit patients. And find what helps and what hinders players in that industry, affecting its results.
So you hear what progress, trends and prospects mean. And you assess what the future holds.
Companies and 2018 market value – find commercial potential
What happens next? Our study predicts that overall world market will reach $10.6bn in 2018, with further expansion to 2024.
Also, from 2014, outsourcing of those operations will increase. There pharmaceutical clients, contract research organisations (CROs), and other participants will benefit. See how, discovering potentials.
You examine companies, including these:
• Johnson & Johnson
• GlaxoSmithKline (GSK)
• Eli Lilly.
And also these specialist firms:
• Cognizant Technology Solutions
From this decade, that pharmaceutical testing industry holds many opportunities. And you examine its technological and commercial possibilities, staying ahead in knowledge.
Ways Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024 helps
In these four ways, that investigation gives you analysis found only in our work, helping you gain recognition for insight:
• Revenues to 2024 at world level from that spending – assess prospects for investments, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia – investigate developed and developing countries for commercial potentials
• Outlooks for established, rising, and emerging product and service providers – explore results, capabilities, news, technologies, activities, and outlooks for success
• Interviews with authorities in the pharmacovigilance industry – scan opinions to help you stay ahead.
Knowledge there found nowhere else, benefiting your searches, analyses, and planning
Our new report gives competitive intelligence, showing where progress, demand, and money exist. Now you explore the pharmacovigilance industry’s future through data exclusive to that study.
So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now find how your choice can benefit your plans, decisions, and authority – increasing your chances of gaining advantages.
Trying our new study on post-marketing testing and drug surveillance lets you explore those trends, opportunities, and sales predictions. Stay ahead there – please get that report here now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view sample pages of this report click here